Pseudobulbar Affect

Avanir Pharmaceuticals releases data on PBA drug

Avanir Pharmaceuticals has announced data on pseudobulbar affect, a neurological condition characterized by disruptive, uncontrollable episodes of laughing or crying, and NUEDEXTA®, the only FDA-approved product for the treatment of PBA. Results will be presented at the Alzheimer's Association International Conference in Copenhagen, Denmark, which runs July 12 through 17.